Literature DB >> 23155136

A comparison of human papillomavirus genotype-specific DNA and E6/E7 mRNA detection to identify anal precancer among HIV-infected men who have sex with men.

Philip E Castle1, Stephen Follansbee, Sylvia Borgonovo, Diane Tokugawa, Lauren M Schwartz, Thomas S Lorey, Brandon LaMere, Julia C Gage, Barbara Fetterman, Teresa M Darragh, Ana Cecilia Rodriguez, Nicolas Wentzensen.   

Abstract

BACKGROUND: Human papillomavirus (HPV) RNA detection is reportedly more specific for the detection of anogenital precancer than HPV DNA but it is unknown whether this is due to detection of RNA or due to HPV genotype restriction.
METHODS: A total of 363 human immunodeficiency virus (HIV)-positive men who have sex with men had two anal cytology samples taken and were evaluated using high-resolution anoscopy and biopsies of visible lesions. Anal specimens were tested for E6/E7 RNA for five carcinogenic HPV genotypes (HPV16, 18, 31, 33, and 45) and tested for the DNA of 13 carcinogenic HPV genotypes.
RESULTS: DNA testing was more likely to be positive than RNA testing (53% vs. 48%; P = 0.02) for the same five HPV genotypes in aggregate. When restricted to five HPV genotypes targeted by the RNA test, the sensitivity to detect anal precancer was the same for DNA and RNA (81%), whereas RNA was more specific than DNA (65% vs. 58%; P = 0.007). In comparison, DNA detection of all 13 carcinogenic HPV genotypes was more sensitive (96% vs. 81%; P = 0.001) but much less specific (65% vs. 33%; P < 0.001) as compared with RNA detection of the five HPV genotypes.
CONCLUSION: After controlling for HPV genotypes, RNA was only slightly more specific than DNA detection for anal precancer. IMPACT: DNA or RNA testing for a subset of the most carcinogenic HPV genotypes may be useful for distinguishing between those HPV-positive men at higher and lower risk of anal precancer and cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23155136      PMCID: PMC3538931          DOI: 10.1158/1055-9965.EPI-12-0984

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  37 in total

Review 1.  Age-specific prevalence of infection with human papillomavirus in females: a global review.

Authors:  Jennifer S Smith; Amy Melendy; Rashida K Rana; Jeanne M Pimenta
Journal:  J Adolesc Health       Date:  2008-10       Impact factor: 5.012

2.  American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.

Authors:  Debbie Saslow; Diane Solomon; Herschel W Lawson; Maureen Killackey; Shalini L Kulasingam; Joanna Cain; Francisco A R Garcia; Ann T Moriarty; Alan G Waxman; David C Wilbur; Nicolas Wentzensen; Levi S Downs; Mark Spitzer; Anna-Barbara Moscicki; Eduardo L Franco; Mark H Stoler; Mark Schiffman; Philip E Castle; Evan R Myers
Journal:  CA Cancer J Clin       Date:  2012-03-14       Impact factor: 508.702

3.  Interrater agreement of anal cytology.

Authors:  Teresa M Darragh; Diane Tokugawa; Philip E Castle; Stephen Follansbee; Sylvia Borgonovo; Brandon J LaMere; Lauren Schwartz; Julia C Gage; Barbara Fetterman; Thomas Lorey; Nicolas Wentzensen
Journal:  Cancer Cytopathol       Date:  2012-07-18       Impact factor: 5.284

4.  PreTect HPV-Proofer: real-time detection and typing of E6/E7 mRNA from carcinogenic human papillomaviruses.

Authors:  Tor Molden; Irene Kraus; Hanne Skomedal; Trine Nordstrøm; Frank Karlsen
Journal:  J Virol Methods       Date:  2007-03-26       Impact factor: 2.014

5.  Human papillomavirus genotype distribution in anal cancer in France: the EDiTH V study.

Authors:  Laurent Abramowitz; Anne-Carole Jacquard; Fatiha Jaroud; Julie Haesebaert; Laurent Siproudhis; Pierre Pradat; Olivier Aynaud; Yann Leocmach; Benoît Soubeyrand; Roger Dachez; Didier Riethmuller; Christiane Mougin; Jean-Luc Pretet; François Denis
Journal:  Int J Cancer       Date:  2010-11-09       Impact factor: 7.396

6.  Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.

Authors:  Silvia de Sanjose; Wim Gv Quint; Laia Alemany; Daan T Geraets; Jo Ellen Klaustermeier; Belen Lloveras; Sara Tous; Ana Felix; Luis Eduardo Bravo; Hai-Rim Shin; Carlos S Vallejos; Patricia Alonso de Ruiz; Marcus Aurelho Lima; Nuria Guimera; Omar Clavero; Maria Alejo; Antonio Llombart-Bosch; Chou Cheng-Yang; Silvio Alejandro Tatti; Elena Kasamatsu; Ermina Iljazovic; Michael Odida; Rodrigo Prado; Muhieddine Seoud; Magdalena Grce; Alp Usubutun; Asha Jain; Gustavo Adolfo Hernandez Suarez; Luis Estuardo Lombardi; Aekunbiola Banjo; Clara Menéndez; Efrén Javier Domingo; Julio Velasco; Ashrafun Nessa; Saibua C Bunnag Chichareon; You Lin Qiao; Enrique Lerma; Suzanne M Garland; Toshiyuki Sasagawa; Annabelle Ferrera; Doudja Hammouda; Luciano Mariani; Adela Pelayo; Ivo Steiner; Esther Oliva; Chris Jlm Meijer; Waleed Fahad Al-Jassar; Eugenia Cruz; Thomas C Wright; Ana Puras; Cecilia Ladines Llave; Maria Tzardi; Theodoros Agorastos; Victoria Garcia-Barriola; Christine Clavel; Jaume Ordi; Miguel Andújar; Xavier Castellsagué; Gloria I Sánchez; Andrzej Marcin Nowakowski; Jacob Bornstein; Nubia Muñoz; F Xavier Bosch
Journal:  Lancet Oncol       Date:  2010-10-15       Impact factor: 41.316

7.  Genotyping of human papillomavirus DNA in anal biopsies and anal swabs collected from HIV-seropositive men with anal dysplasia.

Authors:  Laurent Gohy; Isabella Gorska; Danielle Rouleau; Georges Ghattas; Alexandra de Pokomandy; Sylvie Vézina; Pierre Coté; John Macleod; Guy Allaire; Rachid Hadjeres; Janet R Kornegay; Eduardo Franco; François Coutlée
Journal:  J Acquir Immune Defic Syndr       Date:  2008-09-01       Impact factor: 3.731

8.  Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants.

Authors:  Nicolas Wentzensen; Mark Schiffman; Terence Dunn; Rosemary E Zuna; Michael A Gold; Richard A Allen; Roy Zhang; Mark E Sherman; Sholom Wacholder; Joan Walker; Sophia S Wang
Journal:  Int J Cancer       Date:  2009-11-01       Impact factor: 7.396

9.  Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis.

Authors:  Hugo De Vuyst; Gary M Clifford; Maria Claudia Nascimento; Margaret M Madeleine; Silvia Franceschi
Journal:  Int J Cancer       Date:  2009-04-01       Impact factor: 7.396

10.  Estimating the accuracy of anal cytology in the presence of an imperfect reference standard.

Authors:  William C Mathews; Edward R Cachay; Joseph Caperna; Amy Sitapati; Bard Cosman; Ian Abramson
Journal:  PLoS One       Date:  2010-08-19       Impact factor: 3.240

View more
  10 in total

Review 1.  Human Papillomavirus Laboratory Testing: the Changing Paradigm.

Authors:  Eileen M Burd
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

2.  Strategies for screening and early detection of anal cancers: A narrative and systematic review and meta-analysis of cytology, HPV testing, and other biomarkers.

Authors:  Megan A Clarke; Nicolas Wentzensen
Journal:  Cancer Cytopathol       Date:  2018-05-24       Impact factor: 5.284

3.  5-Year Prospective Evaluation of Cytology, Human Papillomavirus Testing, and Biomarkers for Detection of Anal Precancer in Human Immunodeficiency Virus-Positive Men Who Have Sex With Men.

Authors:  Megan A Clarke; Li C Cheung; Thomas Lorey; Brad Hare; Rebecca Landy; Diane Tokugawa; Julia C Gage; Teresa M Darragh; Philip E Castle; Nicolas Wentzensen
Journal:  Clin Infect Dis       Date:  2019-08-01       Impact factor: 9.079

4.  Risk factors for anal HPV infection and anal precancer in HIV-infected men who have sex with men.

Authors:  Lauren M Schwartz; Philip E Castle; Stephen Follansbee; Sylvia Borgonovo; Barbara Fetterman; Diane Tokugawa; Thomas S Lorey; Vikrant V Sahasrabuddhe; Patricia Luhn; Julia C Gage; Teresa M Darragh; Nicolas Wentzensen
Journal:  J Infect Dis       Date:  2013-08-01       Impact factor: 5.226

5.  Clinical characteristics of women diagnosed with carcinoma who tested positive for cervical and anal high-risk human papillomavirus DNA and E6 RNA.

Authors:  Carlos A R Veo; Sarhan S Saad; José Humberto T G Fregnani; Cristovam Scapulatempo-Neto; Audrey Tieko Tsunoda; Júlio César Possati Resende; Adriana Tarlá Lorenzi; Allini Mafra; Claudia Cinti; Ismael Dale Cotrim; Luciana Albina Reis Rosa; Cristina Mendes de Oliveira; Toni Ricardo Martins; Cristiane Centrone; José Eduardo Levi; Adhemar Longatto-Filho
Journal:  Tumour Biol       Date:  2015-02-13

Review 6.  HPV and anal cancer in HIV-infected individuals: a review.

Authors:  Maarten F Schim van der Loeff; Sofie H Mooij; Oliver Richel; Henry J C de Vries; Jan M Prins
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

7.  Analytic and clinical performance of cobas HPV testing in anal specimens from HIV-positive men who have sex with men.

Authors:  Nicolas Wentzensen; Stephen Follansbee; Sylvia Borgonovo; Diane Tokugawa; Vikrant V Sahasrabuddhe; Jie Chen; Thomas S Lorey; Julia C Gage; Barbara Fetterman; Sean Boyle; Mark Sadorra; Scott Dahai Tang; Teresa M Darragh; Philip E Castle
Journal:  J Clin Microbiol       Date:  2014-06-04       Impact factor: 5.948

8.  Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis.

Authors:  Chunqing Lin; Silvia Franceschi; Gary M Clifford
Journal:  Lancet Infect Dis       Date:  2017-11-17       Impact factor: 25.071

9.  The potential of RNA as a target for national screening of pre-cancer.

Authors:  Frank Karlsen; Margaret Muturi; Cosmas Muyabwa; Lars E Roseng; Serge Bigabwa; Byamungu Chihongola; Lucy Muchiri
Journal:  J Public Health Afr       Date:  2018-12-21

10.  Anal human papilloma viral infection and squamous cell carcinoma: Need objective biomarkers for risk assessment and surveillance guidelines.

Authors:  Santosh Shenoy
Journal:  World J Gastrointest Oncol       Date:  2022-02-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.